Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Contract/Agreement, Product/Service, Funding

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs


ATCC, the world's premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding expected if all project milestones are met. This contract will merge the NIH HIV Reagent Program with the BEI Resources Program under the Biological and Emerging Infections Research Resources Program (BEI-RRP) umbrella. ATCC has managed the BEI Resources Program since 2003 and the NIH HIV Reagent Program since 2020. This important merger will allow researchers to have streamlined access to all priority pathogens for human health under one program.

"Through our successful collaboration with NIAID, we have helped consolidate ten other repositories that provide critical materials to the infectious disease research community," said ATCC chairman and CEO Raymond H. Cypess, DVM, Ph.D. "At ATCC, we understand why curated, high-quality biomaterials, reagents, and products are critical to achieving credible research results. We also recognize why streamlining access to these items is essential so researchers can develop the diagnostic tests, vaccines, and therapies needed to improve human health."

The BEI-RRP will continue to serve as a vital centralized repository of quality-assured organisms, reagents, tools, services, and information related to the NIAID research portfolio. Priority infectious diseases supported by BEI-RRP include Category A, B, and C priority pathogens, emerging infectious diseases, HIV/AIDS, and non-pathogenic microbes. These priorities may change as scientific research and public health needs shift. At the discretion of NIAID, it will also be a resource for materials produced by other government-supported research projects and service programs.

Under the management of ATCC, the BEI-RRP will receive, acquire, authenticate, produce, preserve, store, deaccession, dispose, and distribute most organisms and reagents. The program is expected to serve approximately 15,000 registered researchers from the US and other countries and will include approximately 17,000 unique items in its online catalog.

"Over the past 20 years, we have built a solid rapport with NIAID based on our expertise in biological resource development and management," said Rebecca Bradford, MBA, MS, Vice President of Government Programs within ATCC Federal Solutions. "In doing so, BEI Resources has become instrumental to public health by providing the roadmap and capability to supply critical reagents in response to infectious disease events, resulting in accelerated medical countermeasures. We look forward to continuing to support NIAID's global health efforts."

This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health, and Human Services under Contract No. 75N93024C00001.

About ATCC

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government. With a history of scientific contributions spanning nearly a century, ATCC offers an unmatched combination of being the world's largest and most diverse collection of biological reference materials and data and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization headquartered in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland. To learn more, visit atcc.org.


These press releases may also interest you

at 01:20
Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first quarter of 2024 which continues to be driven by the...

at 01:00
AnX Robotica, the leader in advanced gastrointestinal visualization technologies, is happy to announce a recent publication validating the clinical benefits of using ProScan, the first FDA cleared AI Assisted Reading Tool for Small Bowel Video...

at 00:00
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. As the largest and most academically prestigious international oncology conference in the world, the ASCO Annual Meeting gathers...

12 mai 2024
In a significant stride for urological health, Rigicon Inc. proudly announces groundbreaking enhancements to its ContiReflex® artificial urinary sphincter and Testi10 testicular prosthesis. These state-of-the-art developments, recently showcased at...

12 mai 2024
SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced first preclinical data of its novel human papillomavirus (HPV)-specific T cell...

12 mai 2024
Zai Lab Limited today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYROtm (repotrectinib) for the treatment of adult patients with locally advanced or metastatic...



News published on and distributed by: